Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of $205.34 million. The enterprise value is $137.93 million.
| Market Cap | 205.34M |
| Enterprise Value | 137.93M |
Important Dates
The last earnings date was Thursday, March 21, 2024, before market open.
| Earnings Date | Mar 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 80.84 million shares outstanding.
| Shares Outstanding | 80.84M |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.14% |
| Float | 30.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.83 |
| Forward PS | n/a |
| PB Ratio | 3.50 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.73, with a Debt / Equity ratio of 0.77.
| Current Ratio | 3.73 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.13 |
Financial Efficiency
Return on equity (ROE) is -14.30% and return on invested capital (ROIC) is -13.80%.
| Return on Equity (ROE) | -14.30% |
| Return on Assets (ROA) | -3.90% |
| Return on Capital (ROIC) | -13.80% |
| Revenue Per Employee | $382,626 |
| Profits Per Employee | -$46,989 |
| Employee Count | 179 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.69% in the last 52 weeks. The beta is 0.67, so Innate Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.67 |
| 52-Week Price Change | -21.69% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 2.64 |
| Relative Strength Index (RSI) | 42.36 |
| Average Volume (30 Days) | 9,586 |
Short Selling Information
| Short Interest | 81,275 |
| Short Previous Month | 76,869 |
| Short % of Shares Out | 0.27% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.33 |
Income Statement
In the last 12 months, Innate Pharma had revenue of $68.49 million and -$8.41 million in losses. Loss per share was -$0.10.
| Revenue | 68.49M |
| Gross Profit | 65.78M |
| Operating Income | -13.52M |
| Pretax Income | -8.08M |
| Net Income | -8.41M |
| EBITDA | -687,257 |
| EBIT | -6.12M |
| Loss Per Share | -$0.10 |
Balance Sheet
The company has $98.67 million in cash and $42.57 million in debt, giving a net cash position of $56.09 million or $0.69 per share.
| Cash & Cash Equivalents | 98.67M |
| Total Debt | 42.57M |
| Net Cash | 56.09M |
| Net Cash Per Share | $0.69 |
| Equity / Book Value | 55.39M |
| Book Value Per Share | 0.69 |
| Working Capital | 115.65M |
Cash Flow
In the last 12 months, operating cash flow was -$34.74 million and capital expenditures -$214,501, giving a free cash flow of -$34.96 million.
| Operating Cash Flow | -34.74M |
| Capital Expenditures | -214,501 |
| Free Cash Flow | -34.96M |
| FCF Per Share | -$0.43 |
Margins
Gross margin is 96.05%, with operating and profit margins of -19.74% and -12.28%.
| Gross Margin | 96.05% |
| Operating Margin | -19.74% |
| Pretax Margin | -11.80% |
| Profit Margin | -12.28% |
| EBITDA Margin | -1.00% |
| EBIT Margin | -8.94% |
| FCF Margin | -51.04% |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.88% |
| Shareholder Yield | -1.88% |
| Earnings Yield | -4.34% |
| FCF Yield | -18.02% |
Analyst Forecast
The average price target for Innate Pharma is $11.50, which is 352.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.50 |
| Price Target Difference | 352.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 23.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -0.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.78 |
| Piotroski F-Score | 3 |